HOME >> BIOLOGY >> NEWS
Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases

Berkeley -- An experimental cancer vaccine using defanged listeria bacteria is showing great promise in animal studies, successfully treating new cancers that have spread into the lungs of mice.

The mouse study, reported in the Sept. 21 issue of the journal Proceedings of the National Academy of Sciences by scientists at Cerus Corp. in Concord, Calif., employs a genetically engineered listeria bacteria based on a strain created by coauthor and University of California, Berkeley, microbiologist Daniel Portnoy. Buoyed by the success of the new cancer vaccine, Cerus scientists now are aiming for human trials.

Cerus ultimately hopes to use the genetically engineered listeria vaccine to target cancers such as pancreatic and ovarian cancer, and possibly leukemia and various solid tumors.

The listeria bacteria are uniquely effective vehicles for a cancer vaccine, Portnoy said, because the bacteria incite a strong "innate" response from the immune system and at the same time sneak cancer antigens into cells to optimally stimulate a potent "acquired" immune response. Together, these two independent arms of the human immune system can deliver a one-two punch to cancer cells. Antigens are like a red flag to a bull -- they draw an attack from cells of the immune system -- but the strength of the immune response depends on how the flag is waved.

"This immune therapy uses bacteria that induce both inflammation and an immune response to specific tumor antigens," which together hit the tumor with generalized antitumor chemicals, such as interferon and tumor necrosis factor, as well as activated T-cells that attack and kill the tumor, Portnoy said. "Listeria is the best bug so far to induce that response. With listeria, innate and acquired immunity work in concert."

Portnoy, a professor of molecular and cell biology and of public health and a member of UC Berkeley's Health Sciences Initiative, identified the genes in listeria that make
'"/>

Contact: Robert Sanders
rls@pa.urel.berkeley.edu
510-643-6998
University of California - Berkeley
29-Sep-2004


Page: 1 2 3 4 5

Related biology news :

1. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
2. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
3. Cancer gene MYC emerging as key research target
4. Cancer patient, heal thyself
5. USC researcher named General Motors Cancer Research Scholar
6. Fox Chase Cancer Centers Alfred Knudson Jr. named 2004 Kyoto Prize winner
7. Wilex & Fox Chase Cancer Center begin trial w/ novel compound targeting tumor invasion & metastasis
8. Cancer drug resistance research leads to possible therapeutic target for Alzheimers disease
9. Fox Chase Cancer Center research shows kidney cancer can be diagnosed in urine
10. National Cancer Gene Therapy Foundation gives $4.0 million in research grants
11. Dana-Farber launches Center for Applied Cancer Science

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/23/2019)... ... 23, 2019 , ... Catalent (Booth 3101), the leading global ... health products, is to launch its new OneBio SuiteSM for the integrated development, ... takes place at the Pennsylvania Convention Center in Philadelphia, from June 3-6, 2019. ...
(Date:5/21/2019)... ... May 21, 2019 , ... Experiential tourism, a trend encompassing ... over the last several years. And according to a recent report by Skift, ... In fact, more and more travelers are wanting their journeys to be authentic ...
(Date:5/21/2019)... ... May 20, 2019 , ... The ASGCT Clinical Trials Finder ... therapy throughout the United States. Data curated daily from ClinicalTrials.gov ensures the most up-to-date ... members who volunteered to assist in the development of the ASGCT Clinical Trials ...
Breaking Biology News(10 mins):
(Date:6/11/2019)... ... June 11, 2019 , ... ... from human mesenchymal stem cells (MSC-EV) are able to incorporate into human CD34+ ... a test on mice, MSC-EVs also increased the cells’ ability to lodge into ...
(Date:5/31/2019)... (PRWEB) , ... May 29, 2019 , ... For many ... the toughest forms of cancer demand breakthrough therapies. Advances in immuno-oncology have led to ... patient’s own T cells with engineered T cell receptors known as “CARs”. The CAR ...
(Date:5/31/2019)... ... May 30, 2019 , ... ... Data Integrity on July 08-09, 2019 in Boston, MA. This peer recommended interactive ... device organizations. , The training will kick off with a compendial treatment of ...
(Date:5/31/2019)... ... May 30, 2019 , ... A study released today ... system for the sustained release of human placental stem cell (HPSC)-derived conditioned medium ... to deliver CM into the injured kidney, where it helped restore function and ...
Breaking Biology Technology:
Cached News: